Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease

Nutrients

Volumn 10, Issue 9, 2018, Pages

  Ueda, Norishi ^a   Takasawa, Kazuya ^a,b  

^a Public Central Hospital of Matto Ishikawa   (Japan)

^b Tsurugi Municipal Hospital   (Japan)

Author keywords

C reactive protein; Chronic kidney disease; Ferritin; Hepcidin; Inflammation; Iron deficiency anemia

Indexed keywords

ACONITATE HYDRATASE; ANTIANEMIC AGENT; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 6; C REACTIVE PROTEIN; CD71 ANTIGEN; CERULOPLASMIN; CYTOCHROME B; ERYTHROPOIETIN; FERRITIN; GAMMA INTERFERON; HEME OXYGENASE 1; HEMOGLOBIN; HEPCIDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRON; IRON REGULATORY FACTOR; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; NEOGENIN; NITRIC OXIDE; RNA BINDING PROTEIN; SMAD PROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; AUTACOID; HAMP PROTEIN, HUMAN;

AUTOIMMUNE DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERFERRITINEMIA; IMMUNE RESPONSE; INFLAMMATION; IRON ABSORPTION; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON OVERLOAD; IRON THERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRACTICE GUIDELINE; PREVALENCE; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; TRANSFERRIN SATURATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; ANIMALS; BIOMARKERS; FERRITINS; HEMATINICS; HEPCIDINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; IRON; IRON OVERLOAD; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85052489684     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10091173     Document Type: Review

References (217)

1. Lopez, A.; Cacoub, P.; Macdougall, I.C.; Peyrin-Biroulet, L. Iron deficiency anaemia. Lancet 2016, 387, 907–916. [CrossRef]
2. Levi, M.; Rosselli, M.; Simonetti, M.; Brignoli, O.; Cancian, M.; Masotti, A.; Pegoraro, V.; Cataldo, N.; Heiman, F.; Chelo, M.; et al. Epidemiology of iron deficiency anaemia in four European countries: A population-based study in primary care. Eur. J. Haematol. 2016, 97, 583–593. [CrossRef] [PubMed]
3. Atkinson, M.A.; Furth, S.L. Anemia in children with chronic kidney disease. Nat. Rev. Nephrol. 2011, 7, 635–641. [CrossRef] [PubMed]
4. Iimori, S.; Naito, S.; Noda, Y.; Nishida, H.; Kihira, H.; Yui, N.; Okado, T.; Sasaki, S.; Uchida, S.; Rai, T. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. Nephrology (Carlton) 2015, 20, 601–608. [CrossRef] [PubMed]
5. Geissler, C.; Singh, M. Iron, meat and health. Nutrients 2011, 3, 283–316. [CrossRef] [PubMed]
6. Torti, F.M.; Torti, S.V. Regulation of ferritin genes and protein. Blood 2002, 99, 3505–3516. [CrossRef] [PubMed]
7. Kuragano, T.; Matsumura, O.; Matsuda, A.; Hara, T.; Kiyomoto, H.; Murata, T.; Kitamura, K.; Fujimoto, S.; Hase, H.; Joki, N.; et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014, 86, 845–854. [CrossRef] [PubMed]
8. Ogawa, C.; Tsuchiya, K.; Kanda, F.; Maeda, T. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients. Am. J. Nephrol. 2014, 40, 561–570. [CrossRef] [PubMed]
9. Zitt, E.; Sturm, G.; Kronenberg, F.; Neyer, U.; Knoll, F.; Lhotta, K.; Weiss, G. Iron supplementation and mortality in incident dialysis patients: An observational study. PLoS ONE 2014, 9, e114144. [CrossRef] [PubMed]
10. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to tango: Regulation of mammalian iron metabolism. Cell 2010, 142, 24–38. [CrossRef] [PubMed]
11. Ganz, T. Systemic iron homeostasis. Physiol. Rev. 2013, 93, 1721–1741. [CrossRef] [PubMed]
12. Ueda, N.; Takasawa, K. Role of hepcidin-25 in chronic kidney disease: Anemia and beyond. Curr. Med. Chem. 2017, 24, 1417–1452. [CrossRef] [PubMed]
13. Antonelli, M.; Kushner, I. It’s time to redefine inflammation. FASEB J. 2017, 31, 1787–1791. [CrossRef] [PubMed]
14. Suchdev, P.S.; Williams, A.M.; Mei, Z.; Flores-Ayala, R.; Pasricha, S.R.; Rogers, L.M.; Namaste, S.M. Assessment of iron status in settings of inflammation: Challenges and potential approaches. Am. J. Clin. Nutr. 2017, 106 (Suppl. 6), 1626S–1633S. [CrossRef]
15. Kawaguchi, T.; Tong, L.; Robinson, B.M.; Sen, A.; Fukuhara, S.; Kurokawa, K.; Canaud, B.; Lameire, N.; Port, F.K.; Pisoni, R.L. C-reactive protein and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin. Pract. 2011, 117, c167–c178. [CrossRef] [PubMed]
16. Jairam, A.; Das, R.; Aggarwal, P.K.; Kohli, H.S.; Gupta, K.L.; Sakhuja, V.; Jha, V. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J. Nephrol. 2010, 20, 125–131. [PubMed]
17. Małyszko, J.; Koc-Żórawska, E.; Levin-Iaina, N.; Małyszko, J.; Koźmiński, P.; Kobus, G.; Myśliwiec, M. New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol. Arch. Med. Wewn. 2012, 122, 537–542. [CrossRef] [PubMed]
18. Łukaszyk, E.; Łukaszyk, M.; Koc-Żórawska, E.; Tobolczyk, J.; Bodzenta-Łukaszyk, A.; Małyszko, J. Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press. Res. 2015, 40, 366–373. [CrossRef] [PubMed]
19. Gangat, N.; Wolanskyj, A.P. Anemia of chronic disease. Semin. Hematol. 2013, 50, 232–238. [CrossRef] [PubMed]
20. Susantitaphong, P.; Alqahtani, F.; Jaber, B.L. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am. J. Nephrol. 2014, 39, 130–141. [CrossRef] [PubMed]
21. El-Khatib, M.; Duncan, H.J.; Kant, K.S. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. Nephrology (Carlton) 2006, 11, 400–404. [CrossRef] [PubMed]
22. Singh, A.K.; Coyne, D.W.; Shapiro, W.; Rizkala, A.R.; DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007, 71, 1163–1171. [CrossRef] [PubMed]
23. Malyszko, J.; Malyszko, J.S.; Mysliwiec, M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: Potential role of prohepcidin, hepcidin, and inflammation. Ren. Fail. 2009, 31, 544–548. [CrossRef] [PubMed]
24. Naz, N.; Moriconi, F.; Ahmad, S.; Amanzada, A.; Khan, S.; Mihm, S.; Ramadori, G.; Malik, I.A. Ferritin L is the sole serum ferritin constituent and a positive hepatic acute-phase protein. Shock 2013, 39, 520–526. [CrossRef] [PubMed]
25. Pham, C.G.; Bubici, C.; Zazzeroni, F.; Papa, S.; Jones, J.; Alvarez, K.; Jayawardena, S.; De Smaele, E.; Cong, R.; Beaumont, C.; et al. Ferritin heavy chain upregulation by NF-kB inhibits TNFα-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119, 529–542. [CrossRef] [PubMed]
26. Recalcati, S.; Taramelli, D.; Conte, D.; Cairo, G. Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by inflammatory cytokines: Role of selective iron regulatory protein-2 downregulation. Blood 1998, 91, 1059–1066. [PubMed]
27. Nakanishi, T.; Kuragano, T.; Nanami, M.; Otaki, Y.; Nonoguchi, H.; Hasuike, Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am. J. Nephrol. 2010, 32, 439–446. [CrossRef] [PubMed]
28. Zhao, N.; Zhang, A.S.; Enns, C.A. Iron regulation by hepcidin. J. Clin. Investig. 2013, 123, 2337–2343. [CrossRef] [PubMed]
29. Zhao, N.; Maxson, J.E.; Zhang, R.H.; Wahedi, M.; Enns, C.A.; Zhang, A.S. Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver. J. Biol. Chem. 2016, 291, 12322–12335. [CrossRef] [PubMed]
30. Zhao, N.; Nizzi, C.P.; Anderson, S.A.; Wang, J.; Ueno, A.; Tsukamoto, H.; Eisenstein, R.S.; Enns, C.A.; Zhang, A.S. Low intracellular iron increases the stability of matriptase-2. J. Biol. Chem. 2015, 290, 4432–4446. [CrossRef] [PubMed]
31. Silvestri, L.; Pagani, A.; Camaschella, C. Furin-mediated release of soluble hemojuvelin: A new link between hypoxia and iron homeostasis. Blood 2008, 111, 924–931. [CrossRef] [PubMed]
32. Wichaiyo, S.; Yatmark, P.; Morales Vargas, R.E.; Sanvarinda, P.; Svasti, S.; Fucharoen, S.; Morales, N.P. Effect of iron overload on furin expression in wild-type and β-thalassemic mice. Toxicol. Rep. 2015, 2, 415–422. [CrossRef] [PubMed]
33. Canali, S.; Vecchi, C.; Garuti, C.; Montosi, G.; Babitt, J.L.; Pietrangelo, A. The SMAD pathway is required for hepcidin response during endoplasmic reticulum stress. Endocrinology 2016, 157, 3935–3945. [CrossRef] [PubMed]
34. Shin, D.Y.; Chung, J.; Joe, Y.; Pae, H.O.; Chang, K.C.; Cho, G.J.; Ryter, S.W.; Chung, H.T. Pretreatment with CO-releasing molecules suppresses hepcidin expression during inflammation and endoplasmic reticulum stress through inhibition of the STAT3 and CREBH pathways. Blood 2012, 119, 2523–2532. [CrossRef] [PubMed]
35. Vecchi, C.; Montosi, G.; Zhang, K.; Lamberti, I.; Duncan, S.A.; Kaufman, R.J.; Pietrangelo, A. ER stress controls iron metabolism through induction of hepcidin. Science 2009, 325, 877–880. [CrossRef] [PubMed]
36. Meynard, D.; Sun, C.C.; Wu, Q.; Chen, W.; Chen, S.; Nelson, C.N.; Waters, M.J.; Babitt, J.L.; Lin, H.Y. Inflammation regulates TMPRSS6 expression via STAT5. PLoS ONE 2013, 8, e82127. [CrossRef] [PubMed]
37. Qian, J.; Chen, S.; Huang, Y.; Shi, X.; Liu, C. PGC-1α regulates hepatic hepcidin expression and iron homeostasis in response to inflammation. Mol. Endocrinol. 2013, 27, 683–692. [CrossRef] [PubMed]
38. Kanamori, Y.; Murakami, M.; Sugiyama, M.; Hashimoto, O.; Matsui, T.; Funaba, M. Interleukin-1β (IL-1β) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein δ (C/EBPδ) expression in hepatocytes. J. Biol. Chem. 2017, 292, 10275–10287. [CrossRef] [PubMed]
39. Ruiz-Jaramillo Mde, L.; Guízar-Mendoza, J.M.; Amador-Licona, N.; Gutiérrez-Navarro Mde, J.; Hernández-González, M.A.; Dubey-Ortega, L.A.; Solorio-Meza, S.E. Iron overload as cardiovascular risk factor in children and adolescents with renal disease. Nephrol. Dial. Transplant. 2011, 26, 3268–3273. [CrossRef] [PubMed]
40. Kalantar-Zadeh, K.; Rodriguez, R.A.; Humphreys, M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol. Dial. Transplant. 2004, 19, 141–149. [CrossRef] [PubMed]
41. Hayes, W. Measurement of iron status in chronic kidney disease. Pediatr. Nephrol. 2018. [CrossRef] [PubMed]
42. Kemna, E.; Pickkers, P.; Nemeth, E.; van der Hoeven, H.; Swinkels, D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106, 1864–1866. [CrossRef] [PubMed]
43. Formanowicz, D.; Formanowicz, P. Transferrin changes in haemodialysed patients. Int. Urol. Nephrol. 2012, 44, 907–919. [CrossRef] [PubMed]
44. Gaweda, A.E. Markers of iron status in chronic kidney disease. Hemodial. Int. 2017, 21 (Suppl. 1), S21–S27. [CrossRef]
45. Hackeng, C.M.; Beerenhout, C.M.; Hermans, M.; Van der Kuy, P.H.; Van der Dussen, H.; Van Dieijen-Visser, M.P.; Hamulyák, K.; Van der Sande, F.M.; Leunissen, K.M.; Kooman, J.P. The relationship between reticulocyte hemoglobin content with C-reactive protein and conventional iron parameters in dialysis patients. J. Nephrol. 2004, 17, 107–111. [PubMed]
46. Bovy, C.; Tsobo, C.; Crapanzano, L.; Rorive, G.; Beguin, Y.; Albert, A.; Paulus, J.M. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int. 1999, 56, 1113–1119. [CrossRef] [PubMed]
47. Zaritsky, J.; Young, B.; Wang, H.J.; Westerman, M.; Olbina, G.; Nemeth, E.; Ganz, T.; Rivera, S.; Nissenson, A.R.; Salusky, I.B. Hepcidin—A potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1051–1056. [CrossRef] [PubMed]
48. Mercadal, L.; Metzger, M.; Haymann, J.P.; Thervet, E.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Houillier, P.; Froissart, M.; Stengel, B.; et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS ONE 2014, 9, e99781. [CrossRef] [PubMed]
49. Zaritsky, J.; Young, B.; Gales, B.; Wang, H.J.; Rastogi, A.; Westerman, M.; Nemeth, E.; Ganz, T.; Salusky, I.B. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 2010, 5, 1010–1014. [CrossRef] [PubMed]
50. Ford, B.A.; Eby, C.S.; Scott, M.G.; Coyne, D.W. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010, 78, 769–773. [CrossRef] [PubMed]
51. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 2006, 47 (5 Suppl. 3), S11–S145.
52. Madore, F.; White, C.T.; Foley, R.N.; Barrett, B.J.; Moist, L.M.; Klarenbach, S.W.; Culleton, B.F.; Tonelli, M.; Manns, B.J.; Canadian Society of Nephrology. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int. Suppl. 2008, 110, S7–S11. [CrossRef] [PubMed]
53. Tsubakihara, Y.; Nishi, S.; Akiba, T.; Hirakata, H.; Iseki, K.; Kubota, M.; Kuriyama, S.; Komatsu, Y.; Suzuki, M.; Nakai, S.; et al. 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ther. Apher. Dial. 2010, 14, 240–275. [CrossRef] [PubMed]
54. The Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012, 2, 279–335.
55. Locatelli, F.; Bárány, P.; Covic, A.; De Francisco, A.; Del Vecchio, L.; Goldsmith, D.; Hörl, W.; London, G.; Vanholder, R.; Van Biesen, W.; et al. Kidney disease: Improving global outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol. Dial. Transplant. 2013, 28, 1346–1359. [CrossRef] [PubMed]
56. Macginley, R.; Walker, R.; Irving, M. KHA-CARI Guideline: Use of iron in chronic kidney disease patients. Nephrology (Carlton) 2013, 18, 747–749. [CrossRef] [PubMed]
57. Hung, S.C.; Kuo, K.L.; Tarng, D.C.; Hsu, C.C.; Wu, M.S.; Huang, T.P. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology (Carlton) 2014, 19, 735–739. [CrossRef] [PubMed]
58. National Clinical Guideline Centre (UK). Anaemia Management in Chronic Kidney Disease: Partial Update 2015. In National Institute for Health and Care Excellence (NICE): Clinical Guideline; Loyal College of Physicians: London, UK, 2015.
59. Ratcliffe, L.E.; Thomas, W.; Glen, J.; Padhi, S.; Pordes, B.A.; Wonderling, D.; Connell, R.; Stephens, S.; Mikhail, A.I.; Fogarty, D.G.; et al. Diagnosis and management of iron deficiency in CKD: A summary of the NICE Guideline Recommendations and Their Rationale. Am. J. Kidney Dis. 2016, 67, 548–558. [CrossRef] [PubMed]
60. Mikhail, A.; Brown, C.; Williams, J.A.; Mathrani, V.; Shrivastava, R.; Evans, J.; Isaac, H.; Bhandari, S. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017, 18, 345. [CrossRef] [PubMed]
61. Hamano, T.; Fujii, N.; Hayashi, T.; Yamamoto, H.; Iseki, K.; Tsubakihara, Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int. Suppl. 2015, 5, 23–32. [CrossRef] [PubMed]
62. Bazeley, J.; Bieber, B.; Li, Y.; Morgenstern, H.; de Sequera, P.; Combe, C.; Yamamoto, H.; Gallagher, M.; Port, F.K.; Robinson, B.M. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011, 6, 2452–2461. [CrossRef] [PubMed]
63. Ethier, J.; Mendelssohn, D.C.; Elder, S.J.; Hasegawa, T.; Akizawa, T.; Akiba, T.; Canaud, B.J.; Pisoni, R.L. Vascular access use and outcomes: An international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol. Dial. Transplant. 2008, 23, 3219–3226. [CrossRef] [PubMed]
64. Pisoni, R.L.; Arrington, C.J.; Albert, J.M.; Ethier, J.; Kimata, N.; Krishnan, M.; Rayner, H.C.; Saito, A.; Sands, J.J.; Saran, R.; et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: An instrumental variable analysis. Am. J. Kidney Dis. 2009, 53, 475–491. [CrossRef] [PubMed]
65. Banerjee, T.; Kim, S.J.; Astor, B.; Shafi, T.; Coresh, J.; Powe, N.R. Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am. J. Kidney Dis. 2014, 64, 954–961. [CrossRef] [PubMed]
66. Baracco, R.; Saadeh, S.; Valentini, R.; Kapur, G.; Jain, A.; Mattoo, T.K. Iron deficiency in children with early chronic kidney disease. Pediatr. Nephrol. 2011, 26, 2077–2080. [CrossRef] [PubMed]
67. Cusick, S.E.; Mei, Z.; Freedman, D.S.; Looker, A.C.; Ogden, C.L.; Gunter, E.; Cogswell, M.E. Unexplained decline in the prevalence of anemia among US children and women between 1988–1994 and 1999–2002. Am. J. Clin. Nutr. 2008, 88, 1611–1617. [CrossRef] [PubMed]
68. Akbari, M.; Moosazadeh, M.; Tabrizi, R.; Khatibi, S.R.; Khodadost, M.; Heydari, S.T.; Tahami, A.N.; Lankarani, K.B. Estimation of iron deficiency anemia in Iranian children and adolescents: A systematic review and meta-analysis. Hematology 2017, 22, 231–239. [CrossRef] [PubMed]
69. Fishbane, S.; Pollack, S.; Feldman, H.I.; Joffe, M.M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin. J. Am. Soc. Nephrol. 2009, 4, 57–61. [CrossRef] [PubMed]
70. Cappellini, M.D.; Comin-Colet, J.; de Francisco, A.; Dignass, A.; Doehner, W.; Lam, C.S.; Macdougall, I.C.; Rogler, G.; Camaschella, C.; Kadir, R.; et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol. 2017, 92, 1068–1078. [CrossRef] [PubMed]
71. Centers for Disease Control and Prevention (CDC). Iron deficiency—United States, 1999–2000. MMWR Morb. Mortal. Wkly. Rep. 2002, 51, 897–899.
72. Haupt, L.; Weyers, R. Determination of functional iron deficiency status in haemodialysis patients in central South Africa. Int. J. Lab. Hematol. 2016, 38, 352–359. [CrossRef] [PubMed]
73. Knight, T.G.; Ryan, K.; Schaefer, C.P.; D’Sylva, L.; Durden, E.D. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: The role of intravenous iron therapy. J. Manag. Care Pharm. 2010, 16, 605–615. [CrossRef] [PubMed]
74. Kovesdy, C.P.; Estrada, W.; Ahmadzadeh, S.; Kalantar-Zadeh, K. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 435–441. [CrossRef] [PubMed]
75. Bross, R.; Zitterkoph, J.; Pithia, J.; Benner, D.; Rambod, M.; Kovesdy, C.; Kopple, J.D.; Kalantar-Zadeh, K. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am. J. Nephrol. 2009, 29, 571–581. [CrossRef] [PubMed]
76. Cuevas, X.; García, F.; Martín-Malo, A.; Fort, J.; Lladós, F.; Lozano, J.; Pérez-García, R. Risk factors associated with cardiovascular morbidity and mortality in Spanish incident hemodialysis patients: Two-year results from the ANSWER study. Blood Purif. 2012, 33, 21–29. [CrossRef] [PubMed]
77. Kleine, C.E.; Soohoo, M.; Ranasinghe, O.N.; Park, C.; Marroquin, M.V.; Obi, Y.; Rhee, C.M.; Moradi, H.; Kovesdy, C.P.; Kalantar-Zadeh, K.; et al. Association of pre-end-stage renal disease hemoglobin with early dialysis outcomes. Am. J. Nephrol. 2018, 47, 333–342. [CrossRef] [PubMed]
78. Roberts, T.L.; Foley, R.N.; Weinhandl, E.D.; Gilbertson, D.T.; Collins, A.J. Anaemia and mortality in haemodialysis patients: Interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrol. Dial. Transplant. 2006, 21, 1652–1662. [CrossRef] [PubMed]
79. Fort, J.; Cuevas, X.; García, F.; Pérez-García, R.; Lladós, F.; Lozano, J.; Martín-Malo, A.; ANSWER Study. Mortality in incident haemodialysis patients: Time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrol. Dial. Transplant. 2010, 25, 2702–2710. [CrossRef] [PubMed]
80. Avram, M.M.; Blaustein, D.; Fein, P.A.; Goel, N.; Chattopadhyay, J.; Mittman, N. Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. Suppl. 2003, 87, S6–S11. [CrossRef]
81. Macdougall, I.C.; Tomson, C.R.; Steenkamp, M.; Ansell, D. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: An observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. Nephrol. Dial. Transplant. 2010, 25, 914–919. [CrossRef] [PubMed]
82. Shi, Z.; Zhen, S.; Zhou, Y.; Taylor, A.W. Hb level, iron intake and mortality in Chinese adults: A 10-year follow-up study. Br. J. Nutr. 2017, 117, 572–581. [CrossRef] [PubMed]
83. Rheault, M.N.; Molony, J.T.; Nevins, T.; Herzog, C.A.; Chavers, B.M. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis. Kidney Int. 2017, 91, 177–182. [CrossRef] [PubMed]
84. Ishani, A.; Guo, H.; Gilbertson, D.T.; Liu, J.; Dunning, S.; Collins, A.J.; Foley, R.N. Time to target haemoglobin concentration (11 g/dl)—Risk of hospitalization and mortality among incident dialysis patients. Nephrol. Dial. Transplant. 2007, 22, 2247–2255. [CrossRef] [PubMed]
85. Shoji, T.; Niihata, K.; Fukuma, S.; Fukuhara, S.; Akizawa, T.; Inaba, M. Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. Clin. Exp. Nephrol. 2017, 21, 685–693. [CrossRef] [PubMed]
86. Kalantar-Zadeh, K.; McAllister, C.J.; Lehn, R.S.; Liu, E.; Kopple, J.D. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am. J. Kidney Dis. 2004, 43, 671–684. [CrossRef] [PubMed]
87. Koo, H.M.; Kim, C.H.; Doh, F.M.; Lee, M.J.; Kim, E.J.; Han, J.H.; Han, J.S.; Oh, H.J.; Park, J.T.; Han, S.H.; et al. The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS ONE 2014, 9, e87231. [CrossRef] [PubMed]
88. Kalantar-Zadeh, K.; Lee, G.H.; Miller, J.E.; Streja, E.; Jing, J.; Robertson, J.A.; Kovesdy, C.P. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am. J. Kidney Dis. 2009, 53, 823–834. [CrossRef] [PubMed]
89. Ishigami, J.; Onishi, T.; Shikuma, S.; Akita, W.; Mori, Y.; Asai, T.; Kuwahara, M.; Sasaki, S.; Tsukamoto, Y. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: A single-center cohort study. Clin. Exp. Nephrol. 2013, 17, 106–114. [CrossRef] [PubMed]
90. Liu, S.; Zhang, D.L.; Guo, W.; Cui, W.Y.; Liu, W.H. Left ventricular mass index and aortic arch calcification score are independent mortality predictors of maintenance hemodialysis patients. Hemodial. Int. 2012, 16, 504–511. [CrossRef] [PubMed]
91. Ishida, J.H.; Johansen, K.L. Iron and infection in hemodialysis patients. Semin. Dial. 2014, 27, 26–36. [CrossRef] [PubMed]
92. Jenq, C.C.; Hsu, C.W.; Huang, W.H.; Chen, K.H.; Lin, J.L.; Lin-Tan, D.T. Serum ferritin levels predict all-cause and infection-cause 1-year mortality in diabetic patients on maintenance hemodialysis. Am. J. Med. Sci. 2009, 337, 188–194. [CrossRef] [PubMed]
93. Kessler, M.; Hoen, B.; Mayeux, D.; Hestin, D.; Fontenaille, C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993, 64, 95–100. [CrossRef] [PubMed]
94. Park, K.S.; Ryu, G.W.; Jhee, J.H.; Kim, H.W.; Park, S.; Lee, S.A.; Kwon, Y.E.; Kim, Y.L.; Ryu, H.J.; Lee, M.J.; et al. Serum ferritin predicts mortality regardless of inflammatory and nutritional status in patients starting dialysis: A prospective cohort study. Blood Purif. 2015, 40, 209–217. [CrossRef] [PubMed]
95. Kim, T.; Streja, E.; Soohoo, M.; Rhee, C.M.; Eriguchi, R.; Kim, T.W.; Chang, T.I.; Obi, Y.; Kovesdy, C.P.; Kalantar-Zadeh, K. Serum ferritin variations and mortality in incident hemodialysis patients. Am. J. Nephrol. 2017, 46, 120–130. [CrossRef] [PubMed]
96. Brookhart, M.A.; Freburger, J.K.; Ellis, A.R.; Winkelmayer, W.C.; Wang, L.; Kshirsagar, A.V. Comparative short-term safety of sodium ferric gluconate versus iron sucrose in hemodialysis patients. Am. J. Kidney Dis. 2016, 67, 119–127. [CrossRef] [PubMed]
97. Hoen, B.; Paul-Dauphin, A.; Kessler, M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin. Nephrol. 2002, 57, 457–461. [CrossRef] [PubMed]
98. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Gaillard, C.; Van Wyck, D.; Roubert, B.; Nolen, J.G.; Roger, S.D.; FIND-CKD Study Investigators. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 2014, 29, 2075–2084. [CrossRef] [PubMed]
99. Kalantar-Zadeh, K.; Regidor, D.L.; McAllister, C.J.; Michael, B.; Warnock, D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005, 16, 3070–3080. [CrossRef] [PubMed]
100. Karaboyas, A.; Morgenstern, H.; Pisoni, R.L.; Zee, J.; Vanholder, R.; Jacobson, S.H.; Inaba, M.; Loram, L.C.; Port, F.K.; Robinson, B.M. Association between serum ferritin and mortality: Findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study. Nephrol. Dial. Transplant. 2018. [CrossRef] [PubMed]
101. Floege, J.; Gillespie, I.A.; Kronenberg, F.; Anker, S.D.; Gioni, I.; Richards, S.; Pisoni, R.L.; Robinson, B.M.; Marcelli, D.; Froissart, M.; et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int. 2015, 87, 996–1008. [CrossRef] [PubMed]
102. Chauveau, P.; Level, C.; Lasseur, C.; Bonarek, H.; Peuchant, E.; Montaudon, D.; Vendrely, B.; Combe, C. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: A 2-year prospective study. J. Ren. Nutr. 2003, 13, 137–143. [CrossRef] [PubMed]
103. Leonard, M.B.; Donaldson, L.A.; Ho, M.; Geary, D.F. A prospective cohort study of incident maintenance dialysis in children: An NAPRTC study. Kidney Int. 2003, 63, 744–755. [CrossRef] [PubMed]
104. Chavers, B.M.; Roberts, T.L.; Herzog, C.A.; Collins, A.J.; St Peter, W.L. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int. 2004, 65, 266–273. [CrossRef] [PubMed]
105. Van Stralen, K.J.; Krischock, L.; Schaefer, F.; Verrina, E.; Groothoff, J.W.; Evans, J.; Heaf, J.; Ivanov, D.; Kostic, M.; Maringhini, S.; et al. Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol. Dial. Transplant. 2012, 27, 3950–3957. [CrossRef] [PubMed]
106. Dmitrieva, O.; de Lusignan, S.; Macdougall, I.C.; Gallagher, H.; Tomson, C.; Harris, K.; Desombre, T.; Goldsmith, D. Association of anaemia in primary care patients with chronic kidney disease: Cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol. 2013, 14, 24. [CrossRef] [PubMed]
107. Freburger, J.K.; Ng, L.J.; Bradbury, B.D.; Kshirsagar, A.V.; Brookhart, M.A. Changing patterns of anemia management in US hemodialysis patients. Am. J. Med. 2012, 125, 906–914. [CrossRef] [PubMed]
108. Miskulin, D.C.; Zhou, J.; Tangri, N.; Bandeen-Roche, K.; Cook, C.; Ephraim, P.L.; Crews, D.C.; Scialla, J.J.; Sozio, S.M.; Shafi, T.; et al. Trends in anemia management in US hemodialysis patients 2004–2010. BMC Nephrol. 2013, 14, 264. [CrossRef] [PubMed]
109. Charytan, D.M.; Pai, A.B.; Chan, C.T.; Coyne, D.W.; Hung, A.M.; Kovesdy, C.P.; Fishbane, S.; Dialysis Advisory Group of the American Society of Nephrology. Considerations and challenges in defining optimal iron utilization in hemodialysis. J. Am. Soc. Nephrol. 2015, 26, 1238–1247. [CrossRef] [PubMed]
110. Hassan, R.H.; Kandil, S.M.; Zeid, M.S.; Zaki, M.E.; Fouda, A.E. Kidney injury in infants and children with iron-deficiency anemia before and after iron treatment. Hematology 2017, 22, 565–570. [CrossRef] [PubMed]
111. Streja, E.; Kovesdy, C.P.; Greenland, S.; Kopple, J.D.; McAllister, C.J.; Nissenson, A.R.; Kalantar-Zadeh, K. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am. J. Kidney Dis. 2008, 52, 727–736. [CrossRef] [PubMed]
112. Peyrin-Biroulet, L.; Williet, N.; Cacoub, P. Guidelines on the diagnosis and treatment of iron deficiency across indications: A systematic review. Am. J. Clin. Nutr. 2015, 102, 1585–1594. [CrossRef] [PubMed]
113. Takasawa, K.; Takaeda, C.; Maeda, T.; Ueda, N. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Nutrients 2015, 7, 103–118. [CrossRef] [PubMed]
114. Peters, N.O.; Jay, N.; Cridlig, J.; Rostoker, G.; Frimat, L. Targets for adapting intravenous iron dose in hemodialysis: A proof of concept study. BMC Nephrol. 2017, 18, 97. [CrossRef] [PubMed]
115. Rozen-Zvi, B.; Gafter-Gvili, A.; Paul, M.; Leibovici, L.; Shpilberg, O.; Gafter, U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am. J. Kidney Dis. 2008, 52, 897–906. [CrossRef] [PubMed]
116. Albaramki, J.; Hodson, E.M.; Craig, J.C.; Webster, A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 2012, 1, CD007857. [CrossRef] [PubMed]
117. Qunibi, W.Y.; Martinez, C.; Smith, M.; Benjamin, J.; Mangione, A.; Roger, S.D. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol. Dial. Transplant. 2011, 26, 1599–1607. [CrossRef] [PubMed]
118. Pisani, A.; Riccio, E.; Sabbatini, M.; Andreucci, M.; Del Rio, A.; Visciano, B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial. Nephrol. Dial. Transplant. 2015, 30, 645–652. [CrossRef] [PubMed]
119. Agarwal, R.; Rizkala, A.R.; Bastani, B.; Kaskas, M.O.; Leehey, D.J.; Besarab, A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am. J. Nephrol. 2006, 26, 445–454. [CrossRef] [PubMed]
120. Kalra, P.A.; Bhandari, S.; Saxena, S.; Agarwal, D.; Wirtz, G.; Kletzmayr, J.; Thomsen, L.L.; Coyne, D.W. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol. Dial. Transplant. 2016, 31, 646–655. [CrossRef] [PubMed]
121. Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Gaillard, C.; Wyck, D.V.; Meier, Y.; Larroque, S.; Perrin, A.; Roger, S.D. Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial. Clin. Nephrol. 2017, 88, 301–310. [CrossRef] [PubMed]
122. Jenq, C.C.; Tian, Y.C.; Wu, H.H.; Hsu, P.Y.; Huang, J.Y.; Chen, Y.C.; Fang, J.T.; Yang, C.W. Effectiveness of oral and intravenous iron therapy in haemodialysis patients. Int. J. Clin. Pract. 2008, 62, 416–422. [CrossRef] [PubMed]
123. Stoves, J.; Inglis, H.; Newstead, C.G. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol. Dial. Transplant. 2001, 16, 967–974. [CrossRef] [PubMed]
124. Takasawa, K.; Takaeda, C.; Wada, T.; Ueda, N. Optimal serum ferritin levels for iron deficiency anemia during oral iron therapy (OIT) in Japanese hemodialysis patients with minor inflammation and benefit of intravenous iron therapy for OIT-nonresponders. Nutrients 2018, 10, 428. [CrossRef] [PubMed]
125. Ogawa, C.; Tsuchiya, K.; Tomosugi, N.; Kanda, F.; Maeda, K.; Maeda, T. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study. PLoS ONE 2017, 12, e0179608. [CrossRef] [PubMed]
126. Sanai, T.; Ono, T.; Fukumitsu, T. Beneficial effects of oral iron in Japanese patients on hemodialysis. Intern. Med. 2017, 56, 2395–2399. [CrossRef] [PubMed]
127. Kooistra, M.P.; Niemantsverdriet, E.C.; van Es, A.; Mol-Beermann, N.M.; Struyvenberg, A.; Marx, J.J. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol. Dial. Transplant. 1998, 13, 82–88. [CrossRef] [PubMed]
128. Nakanishi, T.; Kuragano, T.; Kaibe, S.; Nagasawa, Y.; Hasuike, Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin. Exp. Nephrol. 2012, 16, 819–826. [CrossRef] [PubMed]
129. Owen, W.F.; Lowrie, E.G. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998, 54, 627–636. [CrossRef] [PubMed]
130. Kalender, B.; Mutlu, B.; Ersöz, M.; Kalkan, A.; Yilmaz, A. The effects of acute phase proteins on serum albumin, transferrin and haemoglobin in haemodialysis patients. Int. J. Clin. Pract. 2002, 56, 505–508. [PubMed]
131. Heidari, B.; Fazli, M.R.; Misaeid, M.A.; Heidari, P.; Hakimi, N.; Zeraati, A.A. A linear relationship between serum high-sensitive C-reactive protein and hemoglobin in hemodialysis patients. Clin. Exp. Nephrol. 2015, 19, 725–731. [CrossRef] [PubMed]
132. Chan, K.E.; Lafayette, R.A.; Whittemore, A.S.; Hlatky, M.A.; Moran, J. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol. Dial. Transplant. 2008, 23, 2948–2956. [CrossRef] [PubMed]
133. Sharain, K.; Hoppensteadt, D.; Bansal, V.; Singh, A.; Fareed, J. Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease. Clin. Appl. Thromb. Hemost. 2013, 19, 303–308. [CrossRef] [PubMed]
134. Aydin, Z.; Gursu, M.; Karadag, S.; Uzun, S.; Sumnu, A.; Doventas, Y.; Ozturk, S.; Kazancioglu, R. The relationship of prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: A controlled study. Ren. Fail. 2014, 36, 1253–1257. [CrossRef] [PubMed]
135. Goyal, K.K.; Saha, A.; Sahi, P.K.; Kaur, M.; Dubey, N.K.; Goyal, P.; Upadhayay, A.D. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study. Clin. Nephrol. 2018, 89, 363–370. [CrossRef] [PubMed]
136. Musanovic, A.; Trnacevic, S.; Mekic, M.; Musanovic, A. The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis. Med. Arch. 2013, 67, 361–364. [CrossRef] [PubMed]
137. Saltissi, D.; Sauvage, D.; Westhuyzen, J. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin. Nephrol. 1998, 49, 45–48. [PubMed]
138. Voulgarelis, M.; Kokori, S.I.; Ioannidis, J.P.; Tzioufas, A.G.; Kyriaki, D.; Moutsopoulos, H.M. Anaemia in systemic lupus erythematosus: Aetiological profile and the role of erythropoietin. Ann. Rheum. Dis. 2000, 59, 217–222. [CrossRef] [PubMed]
139. Van Santen, S.; van Dongen-Lases, E.C.; de Vegt, F.; Laarakkers, C.M.; van Riel, P.L.; van Ede, A.E.; Swinkels, D.W. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011, 63, 3672–3680. [CrossRef] [PubMed]
140. Seyhan, S.; Pamuk, Ö.N.; Pamuk, G.E.; Çakır, N. The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus. Eur. J. Rheumatol. 2014, 1, 92–95. [CrossRef] [PubMed]
141. Cavallaro, F.; Duca, L.; Pisani, L.F.; Rigolini, R.; Spina, L.; Tontini, G.E.; Munizio, N.; Costa, E.; Cappellini, M.D.; Vecchi, M.; et al. Anti-TNF-mediated modulation of prohepcidin improves iron availability in inflammatory bowel disease, in an IL-6-mediated fashion. Can. J. Gastroenterol. Hepatol. 2017, 2017, 6843976. [CrossRef] [PubMed]
142. Stein, J.; Haas, J.S.; Ong, S.H.; Borchert, K.; Hardt, T.; Lechat, E.; Nip, K.; Foerster, D.; Braun, S.; Baumgart, D.C. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany—A real-world evidence analysis. Clinicoecon. Outcomes Res. 2018, 10, 93–103. [CrossRef] [PubMed]
143. Kronbichler, A.; Mayer, G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013, 11, 95. [CrossRef] [PubMed]
144. Ambruzs, J.M.; Walker, P.D.; Larsen, C.P. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin. J. Am. Soc. Nephrol. 2014, 9, 265–270. [CrossRef] [PubMed]
145. Vanarsa, K.; Ye, Y.; Han, J.; Xie, C.; Mohan, C.; Wu, T. Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis Res. Ther. 2012, 14, R182. [CrossRef] [PubMed]
146. Tripathy, R.; Panda, A.K.; Das, B.K. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE. Lupus 2015, 24, 82–89. [CrossRef] [PubMed]
147. Umare, V.; Nadkarni, A.; Nadkar, M.; Rajadhyksha, A.; Khadilkar, P.; Ghosh, K.; Pradhan, V.D. Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosuspatients? J. Postgrad. Med. 2017, 63, 92–95. [PubMed]
148. Ripley, B.J.; Goncalves, B.; Isenberg, D.A.; Latchman, D.S.; Rahman, A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis. 2005, 64, 849–853. [CrossRef] [PubMed]
149. Mohammed, M.F.; Belal, D.; Bakry, S.; Marie, M.A.; Rashed, L.; Eldin, R.E.; El-Hamid, S.A. A study of hepcidin and monocyte chemoattractant protein-1 in Egyptian females with systemic lupus erythematosus. J. Clin. Lab. Anal. 2014, 28, 306–309. [CrossRef] [PubMed]
150. Zhang, X.; Nagaraja, H.N.; Nadasdy, T.; Song, H.; McKinley, A.; Prosek, J.; Kamadana, S.; Rovin, B.H. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 2012, 81, 401–406. [CrossRef] [PubMed]
151. Demirag, M.D.; Haznedaroglu, S.; Sancak, B.; Konca, C.; Gulbahar, O.; Ozturk, M.A.; Goker, B. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern. Med. 2009, 48, 421–426. [CrossRef] [PubMed]
152. Martinelli, M.; Strisciuglio, C.; Alessandrella, A.; Rossi, F.; Auricchio, R.; Campostrini, N.; Girelli, D.; Nobili, B.; Staiano, A.; Perrotta, S.; et al. Serum hepcidin and iron absorption in paediatric inflammatory bowel disease. J. Crohns Colitis 2016, 10, 566–574. [CrossRef] [PubMed]
153. Iqbal, T.; Stein, J.; Sharma, N.; Kulnigg-Dabsch, S.; Vel, S.; Gasche, C. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Dig. Dis. Sci. 2015, 60, 1375–1381. [CrossRef] [PubMed]
154. Ross, D.N. Oral and intravenous iron therapy in the anaemia of rheumatoid arthritis. Ann. Rheum. Dis. 1950, 9, 358–362. [CrossRef] [PubMed]
155. Anuradha, S.; Singh, N.P.; Agarwal, S.K. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Ren. Fail. 2002, 24, 307–313. [CrossRef] [PubMed]
156. Rambod, M.; Kovesdy, C.P.; Kalantar-Zadeh, K. Combined high serum ferritin and low iron saturation in hemodialysis patients: The role of inflammation. Clin. J. Am. Soc. Nephrol. 2008, 3, 1691–1701. [CrossRef] [PubMed]
157. Rafiean-Kopaie, M.; Nasri, H. Impact of inflammation on anemia of hemodialysis patients who were under treatment of recombinant human erythropoietin. J. Ren. Inj. Prev. 2013, 2, 93–95. [PubMed]
158. Tessitore, N.; Girelli, D.; Campostrini, N.; Bedogna, V.; Pietro Solero, G.; Castagna, A.; Melilli, E.; Mantovani, W.; De Matteis, G.; Olivieri, O.; et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol. Dial. Transplant. 2010, 25, 3996–4002. [CrossRef] [PubMed]
159. Gaillard, C.A.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Van Wyck, D.B.; Bansal, S.S.; Cronin, M.; Meier, Y.; Larroque, S.; Roger, S.D.; et al. Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: An analysis of the FIND-CKD trial. PLoS ONE 2016, 11, e0157063. [CrossRef] [PubMed]
160. Yavuz, A.; Akbaş, S.H.; Tuncer, M.; Kolağasi, O.; Cetinkaya, R.; Gürkan, A.; Demirbaş, A.; Gultekin, M.; Akaydin, M.; Ersoy, F.; et al. Influence of inflammation on the relation between markers of iron deficiency in renal replacement therapy. Transplant. Proc. 2004, 36, 41–43. [CrossRef] [PubMed]
161. Uehata, T.; Tomosugi, N.; Shoji, T.; Sakaguchi, Y.; Suzuki, A.; Kaneko, T.; Okada, N.; Yamamoto, R.; Nagasawa, Y.; Kato, K.; et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: A cross-sectional study. Nephrol. Dial. Transplant. 2012, 27, 1076–1083. [CrossRef] [PubMed]
162. Chand, S.; Ward, D.G.; Ng, Z.Y.; Hodson, J.; Kirby, H.; Steele, P.; Rooplal, I.; Bantugon, F.; Iqbal, T.; Tselepis, C.; et al. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J. Nephrol. 2015, 28, 81–88. [CrossRef] [PubMed]
163. Drakou, A.; Margeli, A.; Theodorakopoulou, S.; Agrogiannis, I.; Poziopoulos, C.; Papassotiriou, I.; Vlahakos, D.V. Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose. Blood Cells Mol. Dis. 2016, 59, 100–105. [CrossRef] [PubMed]
164. Lenga, I.; Lok, C.; Marticorena, R.; Hunter, J.; Dacouris, N.; Goldstein, M. Role of oral iron in the management of long-term hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2007, 2, 688–693. [CrossRef] [PubMed]
165. Tsuchida, A.; Paudyal, B.; Paudyal, P.; Ishii, Y.; Hiromura, K.; Nojima, Y.; Komai, M. Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Exp. Ther. Med. 2010, 1, 777–781. [CrossRef] [PubMed]
166. Nagaraju, S.P.; Cohn, A.; Akbari, A.; Davis, J.L.; Zimmerman, D.L. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial. BMC Nephrol. 2013, 14, 64. [CrossRef] [PubMed]
167. Bhandari, S.; Kalra, P.A.; Kothari, J.; Ambühl, P.M.; Christensen, J.H.; Essaian, A.M.; Thomsen, L.L.; Macdougall, I.C.; Coyne, D.W. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol. Dial. Transplant. 2015, 30, 1577–1589. [CrossRef] [PubMed]
168. Rostoker, G.; Griuncelli, M.; Loridon, C.; Magna, T.; Machado, G.; Drahi, G.; Dahan, H.; Janklewicz, P.; Cohen, Y. Reassessment of iron biomarkers for prediction of dialysis iron overload: An MRI study. PLoS ONE 2015, 10, e0132006. [CrossRef] [PubMed]
169. Tanaka, A.; Inaguma, D.; Watanabe, Y.; Ito, E.; Kamegai, N.; Shimogushi, H.; Shinjo, H.; Koike, K.; Otsuka, Y.; Takeda, A. Ferrokinetics is associated with the left ventricular mass index in patients with chronic kidney disease. Acta Cardiol. 2017, 72, 460–466. [CrossRef] [PubMed]
170. Lin, K.C.; Tsai, M.Y.; Chi, C.L.; Yu, L.K.; Huang, L.H.; Chen, C.A. Serum ferritin is associated with arterial stiffness in hemodialysis patients: Results of a 3-year follow-up study. Int. Urol. Nephrol. 2015, 47, 1847–1853. [CrossRef] [PubMed]
171. Reis, K.A.; Guz, G.; Ozdemir, H.; Erten, Y.; Atalay, V.; Bicik, Z.; Ozkurt, Z.N.; Bali, M.; Sindel, S. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int. Heart J. 2005, 46, 255–264. [CrossRef] [PubMed]
172. Hsieh, Y.P.; Huang, C.H.; Lee, C.Y.; Chen, H.L.; Lin, C.Y.; Chang, C.C. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J. Nephrol. 2013, 2, 38–43. [CrossRef] [PubMed]
173. Kuragano, T.; Itoh, K.; Shimonaka, Y.; Kida, A.; Furuta, M.; Kitamura, R.; Yahiro, M.; Nanami, M.; Otaki, Y.; Hasuike, Y.; et al. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol. Dial. Transplant. 2011, 26, 2663–2667. [CrossRef] [PubMed]
174. Li, H.; Feng, S.J.; Su, L.L.; Wang, W.; Zhang, X.D.; Wang, S.X. Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Chin. Med. J. (Engl.) 2015, 128, 1351–1357. [PubMed]
175. Mostovaya, I.M.; Bots, M.L.; van den Dorpel, M.A.; Goldschmeding, R.; den Hoedt, C.H.; Kamp, O.; Levesque, R.; Mazairac, A.H.; Penne, E.L.; Swinkels, D.W.; et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvective TRansport STudy (CONTRAST). PLoS ONE 2014, 9, e84587. [CrossRef] [PubMed]
176. Van der Weerd, N.C.; Grooteman, M.P.; Bots, M.L.; van den Dorpel, M.A.; den Hoedt, C.H.; Mazairac, A.H.; Nubé, M.J.; Penne, E.L.; Wetzels, J.F.; Wiegerinck, E.T.; et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2013, 28, 3062–3071. [CrossRef] [PubMed]
177. Rostoker, G.; Hummel, A.; Chantrel, F.; Ryckelynck, J.P. Therapy of anemia and iron deficiency in dialysis patients: An update. Nephrol. Ther. 2014, 10, 221–227. (In French) [CrossRef] [PubMed]
178. Del Vecchio, L.; Locatelli, F. Clinical practice guidelines on iron therapy: A critical evaluation. Hemodial. Int. 2017, 21 (Suppl. 1), S125–S131. [CrossRef] [PubMed]
179. Al-Hawas, F.; Abdalla, A.H.; Popovich, W.; Mousa, D.H.; al-Sulaiman, M.H.; al-Khader, A.A. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin. Nephrol. Dial. Transplant. 1997, 12, 2801–2802. [CrossRef] [PubMed]
180. Canavese, C.; Bergamo, D.; Ciccone, G.; Burdese, M.; Maddalena, E.; Barbieri, S.; Thea, A.; Fop, F. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2004, 19, 1564–1570. [CrossRef] [PubMed]
181. Rostoker, G.; Griuncelli, M.; Loridon, C.; Magna, T.; Janklewicz, P.; Drahi, G.; Dahan, H.; Cohen, Y. Maximal standard dose of parenteral iron for hemodialysis patients: An MRI-based decision tree learning analysis. PLoS ONE 2014, 9, e115096. [CrossRef] [PubMed]
182. Vaziri, N.D. Safety issues in iron treatment in CKD. Semin. Nephrol. 2016, 36, 112–118. [CrossRef] [PubMed]
183. Locatelli, F.; Mazzaferro, S.; Yee, J. Iron therapy challenges for the treatment of nondialysis CKD patients. Clin. J. Am. Soc. Nephrol. 2016, 11, 1269–1280. [CrossRef] [PubMed]
184. Agarwal, R.; Kusek, J.W.; Pappas, M.K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015, 88, 905–914. [CrossRef] [PubMed]
185. Litton, E.; Xiao, J.; Ho, K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 2013, 347, f4822. [CrossRef] [PubMed]
186. Bailie, G.R.; Larkina, M.; Goodkin, D.A.; Li, Y.; Pisoni, R.L.; Bieber, B.; Mason, N.; Tong, L.; Locatelli, F.; Marshall, M.R.; et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015, 87, 162–168. [CrossRef] [PubMed]
187. Miskulin, D.C.; Tangri, N.; Bandeen-Roche, K.; Zhou, J.; McDermott, A.; Meyer, K.B.; Ephraim, P.L.; Michels, W.M.; Jaar, B.G.; Crews, D.C.; et al. Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous iron exposure and mortality in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 2014, 9, 1930–1939. [CrossRef] [PubMed]
188. Drüeke, T.; Witko-Sarsat, V.; Massy, Z.; Descamps-Latscha, B.; Guerin, A.P.; Marchais, S.J.; Gausson, V.; London, G.M. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002, 106, 2212–2217. [CrossRef] [PubMed]
189. Kim, S.M.; Lee, C.H.; Oh, Y.K.; Joo, K.W.; Kim, Y.S.; Kim, S.; Lim, C.S. The effects of oral iron supplementation on the progression of anemia and renal dysfunction in patients with chronic kidney disease. Clin. Nephrol. 2011, 75, 472–479. [CrossRef] [PubMed]
190. Agarwal, R.; Rizkala, A.R.; Kaskas, M.O.; Minasian, R.; Trout, J.R. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int. 2007, 72, 638–642. [CrossRef] [PubMed]
191. ′-deoxyguanosine levels. Nephrol. Dial. Transplant. 2007, 22, 1407–1412. [CrossRef] [PubMed]
192. Yahiro, M.; Kuragano, T.; Kida, A.; Kitamura, R.; Furuta, M.; Hasuike, Y.; Otaki, Y.; Nonoguchi, H.; Nakanishi, T. The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients. Clin. Exp. Nephrol. 2012, 16, 448–455. [CrossRef] [PubMed]
193. Wish, J.B. Anemia management under a bundled payment policy for dialysis: A preview for the United States from Japan. Kidney Int. 2011, 79, 265–267. [CrossRef] [PubMed]
194. Kato, S.; Lindholm, B.; Yuzawa, Y.; Tsuruta, Y.; Nakauchi, K.; Yasuda, K.; Sugiura, S.; Morozumi, K.; Tsuboi, N.; Maruyama, S. High ferritin level and malnutrition predict high risk of infection-related hospitalization in incident dialysis patients: A Japanese prospective cohort study. Blood Purif. 2016, 42, 56–63. [CrossRef] [PubMed]
195. Ramanathan, G.; Olynyk, J.K.; Ferrari, P. Diagnosing and preventing iron overload. Hemodial. Int. 2017, 21 (Suppl. 1), S58–S67. [CrossRef] [PubMed]
196. Canavese, C.; Bergamo, D.; Ciccone, G.; Longo, F.; Fop, F.; Thea, A.; Martina, G.; Piga, A. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004, 65, 1091–1098. [CrossRef] [PubMed]
197. Ghoti, H.; Rachmilewitz, E.A.; Simon-Lopez, R.; Gaber, R.; Katzir, Z.; Konen, E.; Kushnir, T.; Girelli, D.; Campostrini, N.; Fibach, E.; et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur. J. Haematol. 2012, 89, 87–93. [CrossRef] [PubMed]
198. Vaziri, N.D. Epidemic of iron overload in dialysis population caused by intravenous iron products: A plea for moderation. Am. J. Med. 2012, 125, 951–952. [CrossRef] [PubMed]
199. Nissenson, A.R.; Berns, J.S.; Sakiewicz, P.; Ghaddar, S.; Moore, G.M.; Schleicher, R.B.; Seligman, P.A. Clinical evaluation of heme iron polypeptide: Sustaining a response to rHuEPO in hemodialysis patients. Am. J. Kidney Dis. 2003, 42, 325–330. [CrossRef]
200. Tanemoto, M.; Ishimoto, Y.; Saito, H. Oral low-dose ferric citrate is a useful iron source for hyperphosphatemic hemodialysis patients: A case series. Blood Purif. 2017, 43, 97–100. [CrossRef] [PubMed]
201. Pandey, R.; Daloul, R.; Coyne, D.W. Iron treatment strategies in dialysis-dependent CKD. Semin. Nephrol. 2016, 36, 105–111. [CrossRef] [PubMed]
202. Malovrh, M.; Hojs, N.; Premru, V. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents. Artif. Organs 2011, 35, 63–68. [CrossRef] [PubMed]
203. Deira, J.; González-Sanchidrián, S.; Polanco, S.; Cebrián, C.; Jiménez, M.; Marín, J.; Gómez-Martino, J.R.; Fernández-Pereira, L.; Tabernero, J. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients. Ren. Fail. 2016, 38, 1076–1081. [CrossRef] [PubMed]
204. Schiesser, D.; Binet, I.; Tsinalis, D.; Dickenmann, M.; Keusch, G.; Schmidli, M.; Ambühl, P.M.; Lüthi, L.; Wüthrich, R.P. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol. Dial. Transplant. 2006, 21, 2841–2845. [CrossRef] [PubMed]
205. Strauss, W.E.; Dahl, N.V.; Li, Z.; Lau, G.; Allen, L.F. Ferumoxytol versus iron sucrose treatment: A post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. BMC Hematol. 2016, 16, 20. [CrossRef] [PubMed]
206. Rath, T.; Florschütz, K.; Kalb, K.; Rothenpieler, U.; Schletter, J.; Seeger, W.; Zinn, S. Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis-the IDIRA Study. Nephron Clin. Pract. 2010, 114, c81–c88. [CrossRef] [PubMed]
207. Gupta, A.; Lin, V.; Guss, C.; Pratt, R.; Ikizler, T.A.; Besarab, A. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 2015, 88, 1187–1194. [CrossRef] [PubMed]
208. Ferrari, P.; Mallon, D.; Trinder, D.; Olynyk, J.K. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) 2010, 15, 344–349. [CrossRef] [PubMed]
209. Pergola, P.E.; Spinowitz, B.S.; Hartman, C.S.; Maroni, B.J.; Haase, V.H. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016, 90, 1115–1122. [CrossRef] [PubMed]
210. Martin, E.R.; Smith, M.T.; Maroni, B.J.; Zuraw, Q.C.; deGoma, E.M. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am. J. Nephrol. 2017, 45, 380–388. [CrossRef] [PubMed]
211. Besarab, A.; Provenzano, R.; Hertel, J.; Zabaneh, R.; Klaus, S.J.; Lee, T.; Leong, R.; Hemmerich, S.; Yu, K.H.; Neff, T.B. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol. Dial. Transplant. 2015, 30, 1665–1673. [CrossRef] [PubMed]
212. Besarab, A.; Chernyavskaya, E.; Motylev, I.; Shutov, E.; Kumbar, L.M.; Gurevich, K.; Chan, D.T.; Leong, R.; Poole, L.; Zhong, M.; et al. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol. 2016, 27, 1225–1233. [CrossRef] [PubMed]
213. Brigandi, R.A.; Johnson, B.; Oei, C.; Westerman, M.; Olbina, G.; de Zoysa, J.; Roger, S.D.; Sahay, M.; Cross, N.; McMahon, L.; et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2a randomized trial. Am. J. Kidney Dis. 2016, 67, 861–871. [CrossRef] [PubMed]
214. Kaysen, G.A. Biochemistry and biomarkers of inflamed patients: Why look, what to assess. Clin. J. Am. Soc. Nephrol. 2009, 4 (Suppl. 1), S56–S63. [CrossRef]
215. Hsu, P.Y.; Lin, C.L.; Yu, C.C.; Chien, C.C.; Hsiau, T.G.; Sun, T.H.; Huang, L.M.; Yang, C.W. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients—A prospective cross-over study. J. Nephrol. 2004, 17, 693–700. [PubMed]
216. Sarafidis, P.A.; Rumjon, A.; MacLaughlin, H.L.; Macdougall, I.C. Obesity and iron deficiency in chronic kidney disease: The putative role of hepcidin. Nephrol. Dial. Transplant. 2012, 27, 50–57. [CrossRef] [PubMed]
217. Sanad, M.; Osman, M.; Gharib, A. Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: A case control study. Ital. J. Pediatr. 2011, 37, 34. [CrossRef] [PubMed]